Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAJAK: DOACs vs Aspirin in JAK2V617F-positive MPNs
NCT05198960Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Jul 2022
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apixaban and rivaroxaban in Myeloproliferative Neoplasm (MPN) (2 arms), sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoint: Time to occurrence of arterial or venous thromboembolic events at 24 months. Started Jul 2022; status: recruiting.
02
Drugs
apixabanrivaroxaban
03
Conditions
Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT05198960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198960.